These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38517826)

  • 21. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
    Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
    Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination.
    Chen Z; Liu X; Shang X; Qi K; Zhang S
    Int J Biol Markers; 2021 Dec; 36(4):36-44. PubMed ID: 34709098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired renal cystic disease and tumor markers in chronic hemodialysis patients.
    Polenakovic M; Sikole A; Dzikova S; Polenakovic B; Gelev S
    Int J Artif Organs; 1997 Feb; 20(2):96-100. PubMed ID: 9093887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical application of serum tumor abnormal protein combined with tumor markers in lung cancer patients.
    Tong H; Dan B; Dai H; Zhu M
    Future Oncol; 2022 Apr; 18(11):1357-1369. PubMed ID: 35044835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure.
    Nomura F; Koyama A; Ishijima M; Takano S; Narita M; Nakai T
    Oncol Rep; 1998; 5(2):389-92. PubMed ID: 9468564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.
    Nakamura H; Nishimura T
    Surg Today; 2017 Sep; 47(9):1037-1059. PubMed ID: 28229299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diagnostic values of conventional tumor markers and their combination with chest CT for patients with stageⅠA lung cancer].
    Peng Q; Wu N; Huang Y; Zhao SJ; Tang W; Liang M; Ran YL; Xiao T; Yang L; Liang X
    Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):934-941. PubMed ID: 37968078
    [No Abstract]   [Full Text] [Related]  

  • 31. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
    Yang J; Tang A; Ma J; Sun X; Ming L
    Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
    Yang Q; Zhang P; Wu R; Lu K; Zhou H
    Dis Markers; 2018; 2018():2082840. PubMed ID: 30364165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tumor markers in lung cancer].
    Niho S; Shinkai T
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical role of serum tumor markers SCC, NSE, CA 125, CA 19-9, and CYFRA 21-1 in patients with lung cancer.
    Sun A
    Lab Med; 2023 Nov; 54(6):638-645. PubMed ID: 37052517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor markers in patients with chronic renal failure.
    Filella X; Cases A; Molina R; Jo J; Bedini JL; Revert L; Ballesta AM
    Int J Biol Markers; 1990; 5(2):85-8. PubMed ID: 1704405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers.
    Zhu K; Chen L; He C; Lang Y; Kong X; Qu C; Xu S
    Dis Markers; 2020; 2020():6430459. PubMed ID: 32089756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
    Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
    Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
    Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
    Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
    Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
    J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients.
    Odagiri E; Jibiki K; Takeda M; Sugimura H; Iwachika C; Abe Y; Kihara K; Kihara Y; Itou M; Nomura T
    Am J Nephrol; 1991; 11(5):363-8. PubMed ID: 1725572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.